CTS Corporation Earnings Call Transcripts
Fiscal Year 2026
-
Q3 sales rose 5% YoY, with record adjusted gross margin and EPS, supported by diversified-market growth and strong cash generation. Millar broadens medical and industrial exposure; FY 2026 guidance was raised.
-
Q2 2026 saw 7% revenue growth to $145M, record margins, and strong diversified end market performance, offsetting transportation declines. Full-year guidance was raised, with robust cash flow and new business wins supporting a positive outlook.
-
Diversification beyond automotive has driven growth in medical, industrial, and defense, with strong financial performance and disciplined capital allocation. Medical therapeutics, especially skin tightening, is a standout growth area, while operational excellence and innovation remain strategic priorities.
-
First quarter sales rose 11% year-over-year, led by strong growth in diversified end markets and medical, with gross margin expanding 250 basis points. Full-year guidance was narrowed, and capital allocation remains balanced between growth, acquisitions, and shareholder returns.
-
Diversified markets now drive over half of revenue, with strong growth in medical, industrial, and defense. M&A remains a top priority, targeting high-quality assets in these sectors, while transportation stabilizes with new product launches. Margin expansion and disciplined capital allocation support long-term growth.
Fiscal Year 2025
-
Q4 2025 saw 9% revenue growth and margin expansion, led by strong medical, industrial, and defense performance, while transportation remained flat but secured major new business. 2026 guidance projects continued growth in diversified markets, with sales of $550–$580 million and EPS of $2.30–$2.45.
-
Q3 sales rose 8% year-over-year to $143 million, with strong growth in diversified end markets and margin expansion. Transportation sales declined, but new product wins and a $5 million naval contract boosted outlook. Full-year guidance narrowed, with EPS impacted by tax changes.
-
Q2 2025 saw 4% revenue growth and margin expansion, driven by strong diversified end markets and operational execution. Medical, aerospace, and industrial segments grew, while transportation faced headwinds from China and tariffs. Guidance for 2025 was reaffirmed.
-
Q1 2025 revenue was flat at $126M, with 14% growth in diversified markets offset by a 12% drop in transportation sales. Strong bookings and margin improvement support guidance of $520M–$550M sales and $2.20–$2.35 EPS, though tariffs and market uncertainty remain key risks.
-
Diversification and electrification drive growth, with non-transportation markets now over half of revenue. Gross margins have improved, supported by strong cash flow and disciplined acquisitions, notably SyQwest in defense. Tariff risks are managed, and the outlook remains positive for long-term growth.
-
The company is accelerating diversification into medical, aerospace, defense, and industrial markets, now comprising over half of revenue, while maintaining a disciplined approach to R&D and capital allocation. Despite challenges in transportation and industrial sectors, strong growth in medical and defense, new product innovation, and recent acquisitions support a positive long-term outlook.
Fiscal Year 2024
-
Diversified markets drove 56% of Q4 revenue, with strong growth in medical, industrial, and aerospace/defense offsetting transportation softness. Adjusted gross margin and cash flow improved, and FY2025 guidance anticipates sales of $520M–$550M and EPS of $2.20–$2.35.
-
Q3 revenue reached $132M with adjusted EPS up 17% year-over-year, driven by strong growth in diversified markets and margin expansion. Transportation sales declined, but medical, industrial, and defense segments showed resilience. Full-year sales guidance was lowered, while EPS guidance was maintained.
-
Diversification efforts have shifted revenue toward medical, industrial, aerospace, and defense, with the SyQwest acquisition accelerating this trend. New product launches and a strong acquisition pipeline support a 10% growth target, while financial guidance anticipates margin recovery and steady EPS growth.
-
Q2 2024 sales declined 10% year-over-year to $130 million, with non-transportation segments showing growth and transportation remaining soft. The SyQwest acquisition expands defense market presence and is expected to be accretive in 2025. Full-year guidance was lowered, reflecting more modest growth expectations.